The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

Published:2014-03-27 Issue:6 Volume:4 Page:662-673
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discovery

Author:

Friboulet Luc,Li Nanxin,Katayama Ryohei,Lee Christian C.,Gainor Justin F.,Crystal Adam S.,Michellys Pierre-Yves,Awad Mark M.,Yanagitani Noriko,Kim Sungjoon,Pferdekamper AnneMarie C.,Li Jie,Kasibhatla Shailaja,Sun Frank,Sun Xiuying,Hua Su,McNamara Peter,Mahmood Sidra,Lockerman Elizabeth L.,Fujita Naoya,Nishio Makoto,Harris Jennifer L.,Shaw Alice T.,Engelman Jeffrey A.

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 716 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and efficacy study of an ALK inhibitor AMX6001 in anaplastic large cell lymphoma Karpas299 mice models;European Journal of Medicinal Chemistry Reports;2024-12

2. FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma;2024-09-10

3. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

4. Treatment Advances in Lung Cancer with Leptomeningeal Metastasis;Current Cancer Drug Targets;2024-09

5. In-silico QSAR Modeling for Identification of Novel Anticancer Agent as;PHYS CHEM RES;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP